(MENAFN- GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights
Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025 Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025 Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters presented that highlight the translational power of the Proteograph Ended the year with approximately $240.6 million of cash, cash equivalents and investments
“2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter," said Omid Farokhzad, Chair and CEO of Seer. "Despite this persistently challenging funding environment, we made meaningful progress across our business. Our installed base grew significantly, consumable kit volume increased, the number of publications expanded throughout the year, and the Proteograph was selected to power multiple population-scale studies. I am more confident than ever in our opportunities in 2026 and beyond.”
Fourth Quarter 2025 Financial Results
Revenue was $4.2 million for the fourth quarter of 2025, a 5% increase from $4.0 million for the corresponding prior year period, primarily due to higher product revenue in the quarter. Product revenue for the fourth quarter of 2025 was $2.8 million and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $1.2 million for the fourth quarter of 2025 and primarily consisted of revenue related to Seer Technology Access Center service projects. Other revenue was $128 thousand for the fourth quarter of 2025.
Gross profit was $2.2 million and gross margin was 52% for the fourth quarter of 2025.
Operating expenses were $19.6 million for the fourth quarter of 2025, including $3.2 million of stock-based compensation, a decrease of 23% compared to $25.5 million for the corresponding prior year period, including $6.0 million of stock-based compensation. The decrease in operating expenses was primarily driven by a reduction in stock-based compensation, laboratory expenses, and professional services.
Net loss was $16.0 million for the fourth quarter of 2025, compared to $21.7 million for the corresponding prior year period.
Full Year 2025 Financial Results
Revenue was $16.6 million for the full year 2025, a 17% increase from $14.2 million for the corresponding prior year period, driven by increased product sales and service revenue during the period. Product revenue for the full year 2025 was $11.2 million, including $5 thousand of related party revenue, and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $4.9 million for the full year 2025, including $755 thousand of related party revenue, and primarily consisted of revenue related to Seer Technology Access Center service projects. Other revenue was $459 thousand for the full year 2025.
Gross profit was $8.5 million and gross margin was 51% for the full year 2025.
Operating expenses were $86.5 million for the full year 2025, including $15.0 million of stock-based compensation, a decrease of 19% compared to $107.2 million for the corresponding prior year period, including $26.6 million of stock-based compensation. The decrease in operating expenses was primarily driven by a reduction in stock-based compensation, professional services, and laboratory expenses.
Net loss was $73.6 million for the full year 2025, compared to $86.6 million for the corresponding prior year period.
Cash, cash equivalents and investments were approximately $240.6 million as of December 31, 2025.
2026 Guidance
Seer expects full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of approximately 3% at the midpoint over full year 2025.
Webcast Information
Seer will host a conference call to discuss the fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others do not. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit .
Forward Looking Statements
This press release contains“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer's expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2026. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Kelly Gura
...
Media Contact:
Patrick Schmidt
...
SEER, INC.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
|
| | December 31, | |
| | 2025 | | | 2024 | |
| ASSETS | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $ | 47,285 | | | $ | 40,753 | |
| Short-term investments | | | 138,612 | | | | 195,657 | |
| Accounts receivable, net | | | 4,282 | | | | 3,997 | |
| Related party receivables | | | 300 | | | | 379 | |
| Other receivables | | | 1,370 | | | | 1,853 | |
| Inventory | | | 7,795 | | | | 7,436 | |
| Prepaid expenses and other current assets | | | 1,890 | | | | 3,248 | |
| Total current assets | | | 201,534 | | | | 253,323 | |
| Long-term investments | | | 54,686 | | | | 63,103 | |
| Operating lease right-of-use assets | | | 20,488 | | | | 22,791 | |
| Property and equipment, net | | | 14,754 | | | | 18,575 | |
| Restricted cash | | | 524 | | | | 524 | |
| Other assets | | | 4,097 | | | | 8,281 | |
| Total assets | | $ | 296,083 | | | $ | 366,597 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $ | 5,611 | | | $ | 4,621 | |
| Accrued expenses | | | 7,135 | | | | 7,937 | |
| Deferred revenue | | | 341 | | | | 408 | |
| Operating lease liabilities, current | | | 2,575 | | | | 2,312 | |
| Other current liabilities | | | 29 | | | | 50 | |
| Total current liabilities | | | 15,691 | | | | 15,328 | |
| Operating lease liabilities, net of current portion | | | 21,077 | | | | 23,652 | |
| Other noncurrent liabilities | | | 8 | | | | 48 | |
| Total liabilities | | | 36,776 | | | | 39,028 | |
| Commitments and contingencies | | | | | | |
| Stockholders' equity: | | | | | | |
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of
December 31, 2025 and 2024; zero shares issued and outstanding
as of December 31, 2025 and 2024 | | | - | | | | - | |
Class A common stock, $0.00001 par value; 94,000,000 shares authorized
as of December 31, 2025 and 2024; 56,219,599 and 55,083,123
shares issued and outstanding as of December 31, 2025 and
2024, respectively | | | 1 | | | | 1 | |
Class B common stock, $0.00001 par value; 134,268 and 6,000,000 shares
authorized as of December 31, 2025 and 2024, respectively; zero and
4,044,969 shares issued and outstanding as of December 31, 2025 and
2024, respectively | | | - | | | | - | |
| Additional paid-in capital | | | 724,819 | | | | 719,804 | |
| Accumulated other comprehensive gain | | | 459 | | | | 136 | |
| Accumulated deficit | | | (465,972 | ) | | | (392,372 | ) |
| Total stockholders' equity | | | 259,307 | | | | 327,569 | |
| Total liabilities and stockholders' equity | | $ | 296,083 | | | $ | 366,597 | |
Comments
No comment